CDK4在膀胱移行细胞癌中的表达及其临床意义  

Expression of CDK4 in human bladder transitional cell carcinoma and its clinical significance

作　　者：陈晓波[1] 谭建明[1] 陈坚[2] 

机构地区：[1]上海交通大学附属第一人民医院肾移植科,200080 [2]广西医科大学第一附属医院泌尿外科,南宁市530021

出　　处：《实用医学杂志》2006年第4期380-381,共2页The Journal of Practical Medicine

摘　　要：目的:探讨CDK4蛋白在膀胱移行细胞癌(BTCC)中的表达及其临床意义。方法:采用免疫组化方法,测定10例正常膀胱黏膜及40例BTCC标本中的CDK4蛋白的表达。结果:CDK4蛋白在正常膀胱黏膜和BTCC中的阳性表达率分别为0.00%、52.50%(P<0.05)。CDK4蛋白在G1、G2、G3中的阳性表达率依次为36.84%、61.54%、75.00%,差异无显著性(P>0.05);在Tis～T1中CDK4阳性表达率为40.00%,明显低于T2～T4中的73.33%(P<0.05)。结论:CDK4的过度表达可能在BTCC的进展中发挥了重要作用,CDK4可成为一种新的预后判断的参考指标。Objective To investigate the expression and clinical significance of CDK4 protein in bladder transitional cell carcinoma （ BTCC ）. Methods CDK4 protein expression of 40 BTCC and 10 normal bladder tissues were analysed by immunohistochemistry. Results The positive rates of CDK4 were 52. 50% in BTCC and 0.00% in normal bladder tissues （ P〈0.05）. The positive rates of CDK4 in G1, G2 and G3 were 36. 84%, 61.54%, 75.00%, respectively; and no statistically significant difference among the three groups（ P 〉 0.05） . The positive rate of CDK4 in Tis-T1 was significantly lower than that in T2-T4（P〈0.05）. Conclusion CDK4 protein overexpression may play an important role in the development of BTCC. CDK4 may be a novel prognostic factor in BTCC.

关 键 词：癌 移行细胞 膀胱肿瘤 免疫组织化学 细胞周期蛋白质依赖激酶类 CDK4蛋白 

分 类 号：R737.14[医药卫生—肿瘤]